Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609708 | 0.85 | RIPK1 (0.57) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL598533 | 0.81 | RIPK1 (0.53) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL6280516 | 0.79 | RIPK1 (0.67) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL1412787 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL5961079 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL1861354 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL3080030 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL1299997 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 | |
| SCHEMBL19160055 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL1144320 | 0.79 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2489660-A1 | Methods for making central nervous system agents that are TRPV1 antagonists | Abbott Laboratories (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| US-8232411-B2 | Methods for making central nervous system agents that are TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| US-8026256-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2323989-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2017265-B1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0971904-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | RIPK1 3151/4885TAAR1 1916/4885TRPA1 104/4885 |
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | TRPV1, TRPV2, OPRL1 | RIPK1 3058/4885TAAR1 415/4885TRPA1 6/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | RIPK1 3729/4885TAAR1 1930/4885TRPA1 1246/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | RIPK1 3729/4885TAAR1 1930/4885TRPA1 1246/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | RIPK1 3106/4885TAAR1 704/4885TRPA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.